Sort

Search

01/10/2023 Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E, Rodríguez-Abreu D, Simó M, Massutí B, Juan O, Huidobro G, López R, De Castro J, Estival A, Mosquera J, Sullivan I, Felip E, Blasco A, Guirado M, Pereira E, Vilariño N, Navarro V, Bruna J. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).. JOURNAL OF CLINICAL ONCOLOGY. 2023; 41(28)DOI:10.1200/JCO.22.02561. PMID:37603816. IF:42.100(Q1/1D).
01/10/2023 Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Puertas B, González-Calle V, Sureda A, Moreno MJ, Oriol A, González E, Rosiñol L, López J, Escalante F, Martínez-Lopez J, Carrillo E, Clavero E, Ríos-Tamayo R, Rey-Bua B, González-Rodríguez AP, Dourdil V, De Arriba F, González S, Pérez-de-Oteyza J, Hernández MT, García-Mateo A, Bargay J, Bladé J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos MV. Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.. HAEMATOLOGICA. 2023; 108(10)DOI:10.3324/haematol.2022.282490. PMID:37102598. IF:10.100(Q1/2D).
01/10/2023 Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage: A Secondary Analysis of the RACECAT Randomized Clinical Trial.
Ramos-Pachón A, Rodríguez-Luna D, Martí-Fàbregas J, Millán M, Bustamante A, Martínez-Sánchez M, Serena J, Terceño M, Vera-Cáceres C, Camps-Renom P, Prats-Sánchez L, Rodríguez-Villatoro N, Cardona-Portela P, Urra X, Solà S, Del Mar Escudero M, Salvat-Plana M, Ribó M, Abilleira S, Pérez de la Ossa N, Silva Y. Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage: A Secondary Analysis of the RACECAT Randomized Clinical Trial.. JAMA Neurology. 2023; 80(10)DOI:10.1001/jamaneurol.2023.2754. PMID:37603325. IF:20.900(Q1/1D).
01/10/2023 Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy.
Schiava M, Ikenaga C, Topf A, Caballero-Ávila M, Chou TF, Li S, Wang F, Daw J, Stojkovic T, Villar-Quiles R, Nishino I, Inoue M, Nishimori Y, Saito Y, Katsuno M, Noda S, Ito C, Otsuka M, Nahir S, Manousakis G, Walk D, Quinn C, Alfano L, Sahenk Z, Tasca G, Monforte M, Sabatelli M, Bisogni G, Oldfors A, Rydeliu A, Pal E, Paradas C, Velez B, De Bleecker JL, Farugia ME, Longman C, Harms MB, Ralston S, Zanoteli E, Macedo Serafim da Silva A, Sotoca J, Juntas-Morales R, Bevilacqua J, Balart M, Talbot S, Straub V, Guglieri M, Marini-Bettolo C, Diaz-Manera J, Weihl CC. Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy.. Neurology-Genetics. 2023; 9(5)DOI:10.1212/NXG.0000000000200093. PMID:37588275. IF:(Q/D).
01/10/2023 The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes.
Bermejo S, González E, López-Revuelta K, Ibernon M, López D, Martín-Gómez A, Garcia-Osuna R, Linares T, Díaz M, Martín N, Barros X, Marco H, Navarro MI, Esparza N, Elias S, Coloma A, Robles NR, Agraz I, Poch E, Rodas L, Lozano V, Fernández-Fernández B, Hernández E, Martínez MI, Stanescu RI, Moirón JP, García-Fernández N, Goicoechea M, Calero F, Bonet J, Liaño F, Pascual J, Bestard O, Praga M, Fulladosa X, Soler MJ. The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes.. Clinical Kidney Journal. 2023; 16(10)DOI:10.1093/ckj/sfad142. PMID:37779839. IF:(Q/D).
01/10/2023 GRADE guidance 23: considering cost-effectiveness evidence in moving from evidence to health-related recommendations.
Xie F, Shemilt I, Vale L, Ruiz F, Drummond MF, Lord J, Herrmann KH, Rojas MX, Zhang Y, Canelo-Aybar C, Alonso-Coello P, Shamliyan T, Schünemann HJ. GRADE guidance 23: considering cost-effectiveness evidence in moving from evidence to health-related recommendations.. JOURNAL OF CLINICAL EPIDEMIOLOGY. 2023; 162DOI:10.1016/j.jclinepi.2023.08.001. PMID:37597696. IF:7.300(Q1/1D).